More Than Ever, Diversity and Inclusion Matter at Eli Lilly and Company
Lilly’s Dave Ricks is passionate about diversity and inclusion at a crucial time.
Lilly’s Dave Ricks is passionate about diversity and inclusion at a crucial time.
Quantum computing has the potential to significantly accelerate, enhance the quality of, and reduce the costs of drug discovery.
Teams often struggle to execute external licensing agreements and M&A transactions that can supplement internal innovation and revenue. Six factors can enhance performance.
A big part of improving immunotherapy for patients may lie in digital technology and analytics.
What happens when longstanding channels of interaction no longer function? Companies are fundamentally changing the way they support the delivery of health care.
Champions that want to keep their advantage—and laggards that want to make up some ground—can take three no-regret moves to create value for patients, shareholders, and society as a whole.
With the right strategic thinking, health care systems will finally succeed in delivering the benefits that consumers have come to expect from other industries.
Technology, demographic trends, and new players are all disrupting the industry. To respond, insurers need to make smart choices about how—and where—they operate.
Organizations must build on the momentum from their response to the crisis, delivering better care at lower overall cost and becoming more resilient to future disruptions.
The health systems that gain the most resilience and agility emerging from the crisis will be those that permanently change the way they work.
Here are some facts to clear up the confusion.
As the current crisis demonstrates, biopharma and medtech companies need to safeguard their networks against unanticipated disruptions. Here’s how.
Industry leaders set themselves apart with five key practices.
The medtech industry is poised for strong growth but faces challenges too. For private equity investors, making sense of the market requires understanding the range of investment themes.
A big gap in our overall testing capability remains unfilled—the ability to tell people quickly and reliably if they have been infected.
As the vaccine rollout continues across the United States, BCG is surveying individuals to learn what’s preventing or discouraging people from getting their shots and to uncover the insights that will help business and government chart a path to the postpandemic future.
What has worked, what can be improved, and what needs to be reimagined so that we are better prepared for the next pandemic and better able to improve health in the world’s poorest nations?
BCG Managing Director & Partner Johanna Benesty looks at barriers to "equitable access"—making sure COVID-19 therapeutics are available to all—while sharing a creative approach to vaccine research and development.
